// App-Quantinova.ai

1208 : Combination effect of afatinib and BI836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC cells

Researchers

Presenter

  • Tohru Ohmori

Principal Investigators

  • Toshimitsu Yamaoka

  • Satoru Arata

  • Motoi Ohba

  • Yasunori Murata

  • Yasunari Kishida

  • Sojiro Kusumoto

  • Masanao Nakashima

  • Takashi Hirose

  • Tsukasa Ohnishi

  • Kazuto Nishio

Medical Centers

  • Inst Mol Oncol, Showa Univ, Tokyo, Japan

  • Cent Biotechnol, Showa Univ, Tokyo, Japan

  • Div Resp Med and Allergol, Dept Int Med, Showa Univ, Tokyo, Japan

  • Natl Hosp Org, Tokyo Natl Hosp, Tokyo, Japan

  • Dept Genome Biol, Kinki Univ Faculty Med, Osaka, Japan.

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hyperglycemia

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • Insulin-like growth factor

  • Insulin-like growth factor 1

Drug/Treatment

  • Figitumumab

  • BMS-754807

  • Erlotinib hydrochloride

  • gefitinib

  • Afatinib

  • ADW-742

  • Mecasermin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved